GeoVax Labs, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020; unaudited. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies, including candidates for COVID-19, HIV, Zika, hemorrhagic fevers, malaria, and cancer. It had no revenue from product sales; reported revenue came from grants and collaborations.
Financial highlights
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Grant and collaboration revenue | $415,458 | $333,209 | $1,572,037 | $907,382 |
| Research and development expense | $416,756 | $467,674 | $1,687,113 | $1,474,619 |
| General and administrative expense | $435,013 | $291,475 | $1,364,650 | $1,214,189 |
| Operating loss | $(436,311) | $(425,940) | $(1,479,726) | $(1,781,426) |
| Net loss | $(570,648) | $(424,434) | $(1,621,546) | $(1,780,036) |
| Net loss per common share | $(0.73) | $(1,282.28) | $(2.85) | $(14,016.03) |
Revenue increased about 25% in Q3 and 73% for the nine-month period year over year. Q3 net loss widened, largely reflecting $134,427 of interest expense, including debt discount amortization on the convertible debentures. Nine-month net loss narrowed modestly. Loss per share comparisons are heavily affected by the company’s reverse stock splits and changes in weighted-average shares.
Cash flow and liquidity: Cash and cash equivalents were $11.58 million at September 30, 2020, versus $283,341 at December 31, 2019. Working capital was positive $10.81 million, compared with a deficit of $1.57 million. Operating cash use was $1.21 million for the first nine months, versus $1.12 million in 2019; investing cash use was $2,470. Financing provided $12.51 million, primarily from the September equity offering.
Debt and balance sheet: Total liabilities were $942,153, including $201,090 of notes payable. The $1.2 million principal amount of secured convertible debentures, plus accrued interest, converted to equity on September 29; the company reported $134,427 of Q3 interest expense related to financing and other debt costs. A $170,200 PPP loan remained outstanding at quarter-end; the company applied for forgiveness in October, and the application had not been processed as of the report date.
Material changes and financing
- The September public offering of units generated approximately $12.8 million gross and $11.2 million net proceeds. Management said proceeds would support product development, especially COVID-19 and immuno-oncology programs, as well as working capital and other stated purposes.
- The offering and related transactions substantially increased common shares and warrants outstanding. At September 30, 3.85 million warrants were outstanding, in addition to other potential equity awards; the filing warns of potential dilution.
- $1.5 million of deferred compensation owed to current and former executives and directors was exchanged for equity units. The remaining approximately $525,198 was to be paid in cash; deferred-compensation arrangements were discontinued after the offering.
- The company effected a 1-for-20 reverse stock split on September 25, following earlier reverse splits in 2019 and January 2020.
- Accrued expenses declined to $579,585 from $1.85 million at year-end, primarily as accrued payroll and director fees fell. Stockholders’ equity improved from a $1.57 million deficiency to $10.81 million.
Outlook, commentary, and risks
- Management stated that cash resources and current government funding commitments should support planned operations into early 2022. It expects future losses and will need additional funding to continue beyond that period; profitability and positive operating cash flow are not assured.
- Approved grant funds available through September 2021 totaled $417,121. The company expected approximately $290,500 of outstanding vendor and subcontractor commitments to be reimbursable under existing grants.
- Management expects R&D and G&A expenses to increase as development expands. It cited uncertain development timelines and costs, dependence on grants and collaborators, and possible COVID-19-related delays to programs and clinical trials.
- Principal risks include the need for additional capital, unproven product candidates and regulatory approval requirements, reliance on third parties and government support, competition, intellectual-property and licensing risks, and potential shareholder dilution and stock-price volatility.
- Management concluded there was no longer substantial doubt about the company’s ability to continue as a going concern for at least the next 12 months, following the third-quarter financing. The filing also states that disclosure controls and procedures were effective at period-end.
Investor verification points
- Confirm cash burn, grant availability, and the assumptions underlying the stated runway into early 2022.
- Check the status and outcome of the PPP loan forgiveness application and the planned cash payment of deferred compensation.
- Track clinical and preclinical progress, including timing, funding, and any COVID-19-related delays.
- Assess potential dilution from the outstanding warrants, pre-funded warrants, and any future financing.
- Verify whether additional government grants or collaboration funding are secured and whether committed grant-related costs remain reimbursable.